hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06359925 id: Suprazygomatic nerve block briefTitle: Suprazygomatic Nerve Block in Tonsillectomy Patients overallStatus: NOT_YET_RECRUITING date: 2024-10-22 date: 2025-09-20 date: 2026-02-20 date: 2024-04-11 date: 2024-04-11 name: Assiut University class: OTHER briefSummary: The use of suprazygomatic maxillary nerve block to reduce postoperative pain and hospital stay is greater than the use of NSAID and opioids. conditions: Tonsillectomy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 80 type: ESTIMATED name: Suprazygomatic maxillary nerve block using dexmedetomidne and Bupivacaine name: Suprazygomatic maxillary nerve block using Bupivacaine measure: time and amount of first postoperative rescue analgesia after two different blocks using Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) score measure: time and amount of first postoperative rescue analgesia after two different blocks using Paediatric Anaesthesia Emergence Delirium (PAED) scale measure: Parents satisfaction score sex: ALL minimumAge: 3 Years maximumAge: 10 Years stdAges: CHILD hasResults: False
nctId: NCT06359912 id: CNYX-EPCs-002-1 briefTitle: Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia overallStatus: RECRUITING date: 2024-04 date: 2025-04 date: 2025-07 date: 2024-04-11 date: 2024-04-11 name: Allife Medical Science and Technology Co., Ltd. class: INDUSTRY name: First Affiliated Hospital Xi'an Jiaotong University briefSummary: The purpose of this study is to determine if allogeneic Endothelial Progenitor Cells (EPCs) intravenous infusion to a subject with leg ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain, increase blood flow, and/or cure the leg wound. conditions: Critical Limb Ischemia studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 27 type: ESTIMATED name: EPCs name: Clinical standard treatment (CST) measure: adverse events measure: Painless walking and intermittent claudication distance measure: Blood flow of the affected limb measure: Rutherford grade measure: The area of skin ulcer measure: Vascular Quality of Life Questionnaire-6 score sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hui Shi status: RECRUITING city: Beijing state: Beijing country: China name: Shaoying Lu, Dr role: CONTACT phone: +862985323473 phoneExt: +862985323473 email: xjyfyllh@163.com name: Fanggang Li role: CONTACT phone: 86-18911352611 email: lifanggang@allifetech.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06359899 id: AK0901-2001 briefTitle: A Study to Evaluate the Efficacy, Safety and Tolerability of Oral AK0901 in Children With ADHD overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-09 date: 2024-10 date: 2024-04-11 date: 2024-04-11 name: Shanghai Ark Biopharmaceutical Co., Ltd. class: INDUSTRY briefSummary: This study is a Phase 3, multicenter, dose-optimized, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of oral AK0901 capsules in children 6 to 12 years old with Attention Deficit Hyperactivity Disorder（ADHD）. conditions: ADHD studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: AK0901 capsule name: Placebo measure: To evaluate the efficacy of AK0901 compared to placebo in children 6 to 12 years old with ADHD. measure: Change from baseline in ADHD-RS-5 total score at Week 4. measure: Changes in ADHD-RS-5 inattention subscale score from baseline to each visit in the Double-Blind Treatment Period measure: Changes in ADHD-RS-5 hyperactivity/impulsivity subscale score from baseline to each visit in the Double-Blind Treatment Period. measure: Change in CGI-S score from baseline to each visit in the Double-Blind Treatment Period measure: CGI-I scores from V3 at each visit in the Double-Blind Treatment Period measure: Change in WREMB-R score from baseline to each visit in the Double-Blind Treatment measure: Proportion of subjects with adverse events (AEs) occurring during the study measure: Proportion of subjects with serious adverse events (SAEs) occurring during the study measure: Changes in respiratory rate during the study measure: Changes in heart rate during the study measure: Changes in body temperature during the study measure: Changes in systolic blood pressure during the study measure: Changes in diastolic blood pressure during the study measure: Change from baseline in QT intervals from resting EKGs measure: Change from baseline in QTcF intervals from resting EKGs measure: Change from baseline in heart rate resting EKGs measure: Change from baseline in QRS intervals from resting EKGs measure: Change from baseline in PR intervals from resting EKGs measure: Change in CSHQ score from baseline to each visit in the Double-Blind Treatment Period sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Beijing anding hospital capital medical university city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 facility: Peking university sixth hospital city: Beijing state: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06359886 id: FMASU MD 292/2022 briefTitle: B-lynch Transverse Compression Suture overallStatus: RECRUITING date: 2024-03-20 date: 2025-04 date: 2025-09 date: 2024-04-11 date: 2024-04-11 name: Alexandria University class: OTHER briefSummary: Is B-Lynch transverse compression suture safe and effective in controlling excessive blood loss during conservative management of women with placenta previa? conditions: Blood Loss, Surgical studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: A Pilot Study primaryPurpose: PREVENTION masking: NONE count: 25 type: ESTIMATED name: B-Lynch Transverse Compression Suture measure: Intraoperative blood loss measure: Postoperative blood loss measure: Number of received blood components measure: Peripartum haemoglobin level drop sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Ain Shams University status: RECRUITING city: Cairo zip: 21526 country: Egypt name: Ahmed S Zeerban, Msc role: CONTACT phone: +201003119968 email: Ahmedzeerban@gmail.com lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06359873 id: LAD-AF briefTitle: Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With Hypertension overallStatus: COMPLETED date: 2022-05-01 date: 2022-09-30 date: 2023-05-01 date: 2024-04-11 date: 2024-04-11 name: The Second Affiliated Hospital of Chongqing Medical University class: OTHER briefSummary: Based on the data of inpatients with hypertension and a cross-sectional study with a large sample size, this study aims to find the early warning value of the left anteroposterior atrial diameter for the possible occurrence of atrial fibrillation in patients with hypertension, and compare the advantages and disadvantages of the above two methods for the early warning of the risk of atrial fibrillation in patients with hypertension, so as to achieve the purpose of early identification of high-risk groups that may develop atrial fibrillation. conditions: Atrial Fibrillation conditions: Hypertension,Essential conditions: Left Atrial Dilatation studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 58427 type: ACTUAL name: CHA2DS2-VASc score, C2HEST score, and left atrial diameter (LAD) measure: left atrial diameter (LAD) measure: CHA2DS2-VASc score measure: C2HEST score measure: Atrial fibrillation (AF) measure: Area under the curve (AUC) of LAD and occurrence of AF measure: AUC of CHA2DS2-VASc score and occurrence of AF measure: AUC of C2HEST score and occurrence of AF measure: the LAD cutoff value sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: 2ndChongqingMU city: Chongqing state: Chongqing zip: 400010 country: China lat: 29.56278 lon: 106.55278 hasResults: False
nctId: NCT06359860 id: ST-1898-203 briefTitle: A Study of ST-1898 for Unresectable or Metastatic Melanoma overallStatus: RECRUITING date: 2023-11-07 date: 2025-09 date: 2025-09 date: 2024-04-11 date: 2024-04-11 name: Beijing Scitech-Mq Pharmaceuticals Limited class: INDUSTRY briefSummary: ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT etc. This trial is to evaluate its safety, tolerability, pharmacokinetic, and efficacy in subjects with unresectable or metastatic melanoma.
In phase II, the primary objective is to assess the anti-tumor activities of ST-1898 tablets in subjects with unresectable or metastatic melanoma. The secondary objective is to evaluate the safety of ST-1898 tablets. conditions: Unresectable or Metastatic Melanoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 64 type: ESTIMATED name: ST-1898 tablets measure: Phase Ib Dose Escalation: The Number and frequency of treatment-related adverse events (AEs) and treatment related serious adverse events (SAEs) measure: Phase Ib Dose Escalation: Recommended Phase 2 Dose (RP2D) measure: Phase II Expansion: Objective Response Rate (ORR) measure: Phase Ib Dose Escalation: Trough concentration of ST-1898 measure: Phase Ib Dose Escalation: Peak concentration of ST-1898 measure: Phase Ib Dose Escalation: ORR measure: Phase Ib Dose Escalation: PFS measure: Phase Ib Dose Escalation: DoR measure: Phase Ib Dose Escalation: DCR measure: Phase Ib Dose Escalation: TTP measure: Phase II Dose Expansion: The Number and frequency of treatment-related adverse events and serious adverse events (SAEs) measure: Phase II Dose Expansion: Trough concentration of ST-1898 measure: Phase II Dose Expansion: Peak concentration of ST-1898 measure: Phase II Dose Expansion: PFS measure: Phase II Dose Expansion: DoR measure: Phase II Dose Expansion: DCR measure: Phase II Dose Expansion: TTP sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking University Cancer Hospital & Institute status: RECRUITING city: Beijing zip: 100142 country: China name: Jun GUO, MD role: CONTACT phone: 0086-10-88121122 email: guoj307@126.co name: Chuanliang CUI, MD role: CONTACT phone: 0086-10-88196348 email: 1008ccl@163.com name: Jun GUO, MD role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06359847 id: ST-1898-202 briefTitle: Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer overallStatus: RECRUITING date: 2023-11-15 date: 2025-12 date: 2025-12 date: 2024-04-11 date: 2024-04-11 name: Beijing Scitech-Mq Pharmaceuticals Limited class: INDUSTRY briefSummary: ST-1898, a multi-targeted tyrosine kinase inhibitor, has demonstrated strong inhibitory activity for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT, etc. The primary purpose of this study is to evaluate the efficacy of ST-1898 tablets in patients with locally advanced or metastatic RAIR-DTC after failure of at least first-line TKI systemic therapy. All subjects will receive ST-1898 180 mg orally once daily until disease progression or intolerable toxicity. conditions: Differentiated Thyroid Carcinoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: ST-1898 tablets measure: Objective Response Rate (ORR) measure: The number and frequency of treatment-related adverse events (AEs) and treatment related serious adverse events (SAEs) measure: PFS measure: PFS6m measure: DCR measure: DOR measure: OS measure: Thyroglobulin (Tg) measure: Thyroglobulin Antibody (TgAb) measure: Pharmacokinetic (PK) Parameter: Tmax measure: Pharmacokinetic (PK) Parameter: T1/2 measure: Pharmacokinetic (PK) Parameter: Cmax measure: Pharmacokinetic (PK) Parameter: AUC sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking Union Medical College Hospital status: RECRUITING city: Beijing state: Beijing zip: 100730 country: China name: Yansong Lin, MD role: CONTACT name: Xin Zhang, MD role: CONTACT name: Yansong Lin, MD role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06359834 id: 4-2023-1693 briefTitle: Comparison of Remimazolam and Propofol Effect on Oxygen Reserve During Endoscopic Retrograde Cholangiopancreatography overallStatus: RECRUITING date: 2024-04-10 date: 2025-04-10 date: 2025-04-30 date: 2024-04-11 date: 2024-04-11 name: Yonsei University class: OTHER briefSummary: Propofol is one of the most commonly used sedative in endoscopic procedures, while its potency to induce respiratory depression may threaten patient safety. Remimazolam is known to less likely induce hemodynamic instability when compared to propofol, yet its favorable effects are not clearly evaluated in endoscopic procedures. Hence, this study aimed to compare hemodynamic effects of remimazolam and propofol, by evaluating oxygen reserve index (ORI) in patients scheduled for endoscopic retrograde cholangiopancreatography. conditions: Hepatobiiliary Diseases Requiring Endoscopic Retrograde Cholangiopancreatography studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 112 type: ESTIMATED name: Remimazolam besylate name: Propofol measure: Incidence of Oxygen Reserve Index (ORI) drop to 0.00 during sedation sex: ALL minimumAge: 20 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Division of Gastroenterology, Department of Internal Medicine, Yonsei Institute of Gastroenterology, Yonsei University College of Medicine status: RECRUITING city: Seoul zip: 120-752 country: Korea, Republic of name: Moon Jae Chung, MD role: CONTACT phone: +82-2-2228-1981 email: mjchung@yuhs.ac lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06359821 id: Z-001 briefTitle: Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-09 date: 2025-04-15 date: 2026-04-15 date: 2024-04-11 date: 2024-04-12 name: Sichuan University class: OTHER briefSummary: A Study to Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry of ZA-001, an Alpha-particle-emitting Radiopharmaceutical, in metastatic castration resistant prostate cancer conditions: Metastatic Prostate Cancer studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 5 type: ESTIMATED name: ZA-001 measure: The absorbed radiation doses (Gray [Gy] /Megabecquerel [MBq] )for whole body and organ measure: Adverse Event sex: MALE minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06359808 id: KY20232370 briefTitle: Clinical Characteristics of Sleep Disorders in Patients With Ulcerative Colitis overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-04-11 date: 2024-04-11 name: Xijing Hospital class: OTHER briefSummary: Ulcerative colitis(UC) is one of the two main forms of inflammatory bowel disease(IBD), which seriously affects the quality of life of patients. Previous studies have demonstrated that more than 60% of IBD patients have sleep disorders, which is emerging as an important risk factor for disease recurrence and poor prognosis. However, the mechanisms by which sleep disorders regulates the occurrence and development of IBD remain undefined. This study aims to explore the clinical characteristics of ulcerative colitis patients with sleep disorders based on the microbiota-gut-brain axis, to analyze the effects of sleep disorders on autonomic nervous function, gut microbiota, and metabolites in UC patients. conditions: Colitis, Ulcerative conditions: Sleep Quality conditions: Gastrointestinal Microbiome conditions: Autonomic Nervous System Imbalance studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 152 type: ESTIMATED measure: Pittsburgh Sleep Quality Index (PSQI) measure: Disease activity measure: Heart Rate Variability (HRV) measure: Functional Magnetic Resonance Imaging measure: Neurotransmitter Agents measure: Gastrointestinal Microbiome measure: Patient Health Questionnaire (PHQ-9) measure: Generalized Anxiety Disorder (GAD-7) measure: Inflammatory Bowel Diseases Questionnaire (IBDQ) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06359795 id: FAPI-TED briefTitle: Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease overallStatus: RECRUITING date: 2023-12-15 date: 2027-12-31 date: 2027-12-31 date: 2024-04-11 date: 2024-04-11 name: Peking University Third Hospital class: OTHER briefSummary: FAPI PET has been developed as a promising approach for the evaluation of fibroinflammatory, such as in inflammatory bowel disease. This prospective study aims to explore the value of 18F-AlF-FAPI PET/CT in assessing the activity of Thyroid Eye Disease (TED) and investigate whether FAPI PET/CT may be superior to 99mTc-DTPA SPECT/CT for the diagnosis, therapy response assessment, and follow-up of TED. conditions: Thyroid Eye Disease studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 50 type: ESTIMATED name: 18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT measure: Diagnostic accuracy measure: The value to predict therapy response measure: Diagnostic accuracy comparison measure: FAPI expression and SUV metrics sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dept. of Nuclear Medicine, Peking University Third Hospital status: RECRUITING city: Beijing state: Beijing zip: 100191 country: China name: Hui Li, Dr. role: CONTACT phone: 86-13121136769 email: huilee1990@163.com name: Lingge Suo, Dr. role: CONTACT phone: 86-010-82264935 email: suolingge_1019@126.com name: Hui Li, Dr. role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06359782 id: NL76082.058.20 briefTitle: Complement Inhibition: Attacking the Overshooting Inflammation @Fter Subarachnoid Hemorrhage (CIAO@SAH) acronym: CIAO@SAH overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-02 date: 2027-02 date: 2024-04-11 date: 2024-04-11 name: Haaglanden Medical Centre class: OTHER name: Leiden University Medical Center name: Takeda briefSummary: Aneurysmal subarachnoid hemorrhage (SAH) can lead to devastating outcomes for patients, like cognitive decline. This is caused by early brain injury (EBI) followed by delayed cerebral ischemia (DCI). Neuroinflammation, triggered by the complement system, has been investigated to be a key mediator in the pathophysiology of EBI and DCI. Inhibition of the complement system is therefore considered to be a potentially important new treatment for SAH.
This trial aims to study the safety and efficacy of C1-inhibitor Cinryze, an approved inhibitor of the complement system, compared to placebo in patients with SAH. By temporarily blocking the complement system we hypothesize limitation of delayed cerebral ischemia and a more favourable clinical outcome for SAH patients due to a decrease in the inflammatory response. conditions: Subarachnoid Hemorrhage, Aneurysmal studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A prospective, multicenter, randomized, double-blind, placebo-controlled, phase II trial. primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 128 type: ESTIMATED name: C1 Esterase Inhibitor Injection [Cinryze] name: Placebo measure: Number of participants with delayed cerebral ischemia (DCI) measure: Number of participants with complications during hospitalization. measure: Number of participants with cerebral infarction on brain CT measure: Number of participants dying measure: Neurological condition measured by Glasgow Coma Scale measure: Complement activity markers measured in serum and CSF measure: Inflammatory markers measured in serum and CSF measure: Number of days in the hospital measure: Number of ICU days measure: Number of ventilator days measure: Clinical outcome measure: Clinical outcome measure: Clinical outcome measure: Clinical outcome measure: Clinical outcome sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06359769 id: GROUPCET briefTitle: Group Cognitive Evolutionary Therapy for Depression acronym: GRCET overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-06-01 date: 2025-12-01 date: 2024-04-11 date: 2024-04-11 name: University of Bucharest class: OTHER briefSummary: The goal of this clinical trial is to measure the effects of Group Cognitive Evolutionary Therapy on mental health, especially on depressive symptoms and anxiety.
The Group Cognitive Evolutionary Therapy group will be compared to the waitlist group to test the efficacy of the intervention. conditions: Depression conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 36 type: ESTIMATED name: Group Cognitive Evolutionary Therapy measure: Depressive symptomatology measure: Anxiety symptomatology measure: Sleep quality measure: Perceived stress measure: Social provisions measure: Satisfaction with life measure: Self-perceived mate value sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06359756 id: BRAIN-SAVE1 briefTitle: Ischemic Postconditioning in Carotid Surgery acronym: BRAIN-SAVE overallStatus: RECRUITING date: 2023-09-01 date: 2024-05-01 date: 2024-09-01 date: 2024-04-11 date: 2024-04-12 name: Institute for Cardiovascular Diseases "Dedinje" class: OTHER briefSummary: Analyzing changes in cerebral oximetry, transcranial Doppler and biomarkers of neuronal ischemic injury and blood-brain barrier integrity assessing the safety and efficacy of ischemic postconditioning in carotid surgery (IPCT). conditions: Ischemic Postconditioning conditions: Carotid Surgery conditions: Stroke conditions: Carotid Artery Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 250 type: ESTIMATED name: Ischemic postconditioning in carotid surgery name: Eversion Carotid Endarterectomy measure: Number of Participants with perioperative stroke measure: Number of Participants with perioperative death sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute for Cardiovascular Diseases Dedinje status: RECRUITING city: Belgrade zip: 11000 country: Serbia name: Jovan Petrović, MD role: CONTACT phone: +381113601705 email: jovanpetrovic1997@gmail.com name: Slobodan Pešić, MD role: SUB_INVESTIGATOR lat: 44.80401 lon: 20.46513 hasResults: False